Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks

FinvizFinviz2026/02/12 23:03
By:Finviz
  • Approval will broaden the NARCAN
    ®
    Nasal Spray portfolio, and improve cost-effectiveness by
    increasing flexibility and distribution efficiency of this life-saving medication 

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN

®
Nasal Spray. This approval expands the NARCAN
®
Nasal Spray product suite to include 6-count and 24-count multipack options, specifically designed to meet the needs of partners distributing higher volumes of naloxone. These new formats offer enhanced flexibility with the same trusted product, benefiting community programs and organizations operating large-scale, multi-site, or high-volume distribution programs.

“At Emergent, we work closely with our partners to develop solutions that help improve delivery, distribution and accessibility of NARCAN

®
Nasal Spray,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “The introduction of NARCAN
®
Nasal Spray multipacks marks a significant step in empowering our partners on the front lines. They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life-saving medication in the event of an opioid overdose emergency.”  

This approval builds on Emergent's ongoing commitment to enhancing NARCAN

®
Nasal Spray accessibility and usability, complementing the recent FDA approval of the NARCAN
®
Nasal Spray Carrying Case in January 2026. These efforts underscore Emergent’s comprehensive approach to equipping individuals and organizations with effective tools to combat opioid overdose deaths. The 6-count and 24-count multipacks will be made available soon to purchase for public interest customers through NARCANDirect
®
, Emergent’s proprietary ordering and distribution platform. These multipacks are an addition to the current portfolio and will not replace existing product formats. Since the prescription launch of NARCAN
®
Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada. Visit NARCAN.com and ReadytoRescue.com to learn more.

About NARCAN

®
 Nasal Spray
NARCAN
®
 Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN
®
 Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 


0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Meta’s “Life-or-Death Lawsuit” Begins Today: 29 State Attorneys General Join Forces to Hold Them Accountable, Defeat Could Lead to $1.4 Trillion “Sky-High” Fine

The lawsuit alleges that Facebook and Instagram were deliberately designed as "addictive products," causing harm to tens of millions of underage users. Meta has estimated its maximum potential fine exposure at $1.4 trillion, nearly matching its current market capitalization. Mark Zuckerberg will personally testify in court, and the verdict may reshape the entire business model of the social media industry.

华尔街见闻2026/08/18 16:01

U.S. Human Resource Stocks Strongly Rebound: AI Resume Boom Makes Recruitment Companies Even More Valuable!

AI has not disrupted the US recruitment industry; instead, the proliferation of AI-generated resumes has increased the value of screening, creating new demand for HR companies. Recruitment stocks such as ManpowerGroup and Robert Half have reported better-than-expected earnings, with their share prices rebounding strongly from lows. AI has also become an efficiency tool for the industry, but valuations are under pressure after the rebound. The long-term trend will depend on the recovery of the US labor market and whether recruitment companies can truly benefit from AI.

华尔街见闻2026/08/18 16:01